| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Recombinant Human Parathyroid Hormone |
| Brand | Natpar® |
| Indication | Is indicated as adjunctive treatment of adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone. |
| Assessment Process | |
| Rapid review commissioned | 05/03/2018 |
| Rapid review completed | 21/05/2018 |
| Rapid review outcome | A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of Natpar compared with the current standard of care. |
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.